Regen BioPharma Leverages Exosome Technologies to Broaden its Survivin Cancer Immunotherapy Portfolio
Regen BioPharma, Inc. (OTC PINK: RGBP, RGBPP) has filed a provisional patent application focused on using survivin-engineered dendritic cells and exosomes to enhance anti-cancer immunity. This approach aims to improve the immune system's ability to target and destroy survivin-expressing tumor cells while sparing healthy tissue. The company draws on prior work with DCellVax for breast cancer treatment and is positioned to diversify its portfolio in the expanding immunotherapy market, which is projected to reach $100 billion globally. CEO David Koos emphasized the potential for new revenue streams through this innovative strategy.
- Filed provisional patent for survivin-engineered dendritic cells and exosomes, enhancing anti-cancer immunity.
- Potential to diversify revenue streams in a rapidly growing $100 billion global immunotherapy market.
- Previous experience with DCellVax for breast cancer may inform future developments.
- None.
Company Expands on Issued Patent to Create Novel Approach to Selectively Killing Tumor Cells
Dendritic cells are the most potent immune cell capable of activating T cells. T cells are the effectors of the immune system and in the present case are the cells that are involved in killing survivin-expressing tumor cells. The cancer marker survivin appears to be present on most of the major cancers but not on non-malignant tissues.
The Company has previously designed dendritic cells for treatment of breast cancer utlizing a process called gene silencing. The current work capitalized on lessons learned in developing DCellVax[1], as well as novel findings regarding utilizing of exosomes, naturally occurring nanoparticles with ability to modulate the immune system.
"The field of immunotherapy is expanding at an unprecedented rate and this is exemplified by the astronomical rise in the use of immunotherapeutic drugs, which now are believed to possess a 100 billion global annual market[2]," said
About
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
[1] Regen BioPharma Completes Preclinical Experiments For dCellVax Breast Cancer Immune Therapy |
[2] Cancer Immunotherapy Market Size & Share Report, 2030 (grandviewresearch.com)
CONTACT INFORMATION
Chairman & Chief Executive Officer
+1-619-722-5505 Phone
+1-619-330-2328 Fax
david.koos@regenbiopharmainc.com
Follow us on Twitter for future updates: https://twitter.com/TheRegenBio
View original content:https://www.prnewswire.com/news-releases/regen-biopharma-leverages-exosome-technologies-to-broaden-its-survivin-cancer-immunotherapy-portfolio-301727330.html
SOURCE
FAQ
What is the recent development from Regen BioPharma regarding cancer treatment?
How does Regen BioPharma's new patent application impact their business?
What market is Regen BioPharma targeting with its new immunity technology?